Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

(Reuters) -Immunovant said on Wednesday its drug for a type of chronic autoimmune disease affecting muscles met the main goal of improving some patients' ability to perform daily activities in a ...

Chronic inflammatory demyelinating polyneuropathy (CIPD) can have a substantial impact on patients everyday life and, ...